Familial haemophagocytic lymphohistiocytosis is a rare and life-threatening immune disorder that requires urgent treatment. Without proper intervention, this condition can rapidly overwhelm the body’s defenses and cause severe damage to vital organs, but advances in medical therapy and stem cell transplantation are offering renewed hope to patients and their families.

Fighting an Immune System in Overdrive

The treatment of familial haemophagocytic lymphohistiocytosis centers on one critical goal: stopping the immune system from attacking the body while preserving enough function to fight real threats like infections. This balancing act is one of the most challenging tasks in modern medicine, because the condition triggers what doctors call a cytokine storm—an overwhelming release of inflammatory proteins that can quickly lead to organ failure and death if left unchecked.^[1]

Treatment decisions depend heavily on how advanced the disease is when diagnosed, the patient’s age, overall health, and whether genetic testing has confirmed one of the known mutations causing the condition. The approach must be swift and decisive. Without treatment, infants with active familial haemophagocytic lymphohistiocytosis typically survive less than two months after symptoms begin, with deaths resulting from progressive organ damage, invasive infections, and uncontrolled bleeding.^[1]

Medical societies and expert groups have developed standardized protocols to guide treatment, recognizing that early intervention dramatically improves survival rates. These guidelines emphasize the importance of starting therapy quickly while simultaneously preparing for the only known cure: stem cell transplantation. At the same time, researchers worldwide are testing new medications and approaches in clinical trials, searching for treatments that can control the disease more effectively with fewer side effects.^[7]

Standard Treatment: Controlling the Storm

The backbone of standard treatment for familial haemophagocytic lymphohistiocytosis involves chemoimmunotherapy—a combination of chemotherapy drugs and immune-suppressing medications designed to calm the overactive immune response. The most widely used treatment protocols are called HLH-94 and HLH-2004, named after the years they were developed and refined through international collaboration.^[1]

The central drug in these protocols is etoposide, a chemotherapy agent that works by reducing the number of activated immune cells, particularly the T lymphocytes and macrophages that are causing widespread tissue damage. Etoposide targets rapidly dividing cells, helping to bring the runaway immune response under control. It is typically given intravenously over several weeks to months, with the dose carefully calculated based on the patient’s body surface area and overall condition.^[8]

Alongside etoposide, patients receive corticosteroids, most commonly dexamethasone. These powerful anti-inflammatory medications work through a different mechanism, suppressing the production of inflammatory cytokines and reducing tissue swelling. Corticosteroids are given in high doses initially, then gradually tapered as the disease comes under control. The combination of etoposide and dexamethasone addresses both the excessive proliferation of immune cells and the inflammatory cascade they trigger.^[9]

Many treatment protocols also include cyclosporine, an immunosuppressive drug originally developed to prevent organ transplant rejection. Cyclosporine works by blocking the activation signals that T cells need to multiply and attack tissues. Some patients receive cyclosporine from the beginning of treatment, while others start it after the initial phase of therapy to maintain disease control while waiting for stem cell transplantation.^[8]

The duration of standard treatment varies considerably depending on how quickly the disease responds and how soon a suitable stem cell donor can be found. Some patients need only a few months of chemoimmunotherapy before proceeding to transplant, while others require extended treatment to achieve adequate disease control. During this time, patients are monitored closely with blood tests measuring inflammation markers, blood cell counts, and organ function.^[1]

Because familial haemophagocytic lymphohistiocytosis severely weakens the immune system even before treatment begins, and because the medications used to control it suppress immunity further, patients face a high risk of serious infections. Antibiotics, antifungal medications, and antiviral drugs are often given preventively throughout treatment. Blood product transfusions—including red blood cells, platelets, and sometimes plasma—are frequently necessary to maintain safe blood counts and clotting function.^[9]

For patients with neurological involvement, where the disease has affected the brain or spinal cord, treatment protocols may include direct administration of chemotherapy into the spinal fluid through lumbar puncture. This approach, called intrathecal therapy, helps medications reach the central nervous system more effectively, as many drugs given intravenously cannot cross the protective blood-brain barrier in sufficient quantities.^[8]

The Definitive Cure: Stem Cell Transplantation

While chemoimmunotherapy can control the symptoms of familial haemophagocytic lymphohistiocytosis, it cannot cure the underlying genetic defect. The only curative treatment is allogeneic hematopoietic stem cell transplantation, commonly called bone marrow transplant. This procedure replaces the patient’s defective immune system with healthy stem cells from a donor, providing a new immune system that functions normally.^[1]

The transplant process begins with finding a suitable donor, ideally a sibling who is a complete genetic match. When a matched sibling is not available, doctors search international donor registries for unrelated donors or consider using partially matched family members or umbilical cord blood as stem cell sources. The search for an appropriate donor can take weeks to months, during which the patient continues receiving medications to keep the disease under control.^[8]

Before the actual transplant, patients undergo a preparative regimen called conditioning, which involves high doses of chemotherapy and sometimes radiation to eliminate the patient’s existing immune and blood-forming cells. This creates space in the bone marrow for the donor cells to engraft and makes the patient’s immune system unable to reject the transplant. The intensity of conditioning varies based on the patient’s condition and the transplant approach used.^[9]

After conditioning, the donor’s stem cells are infused into the patient’s bloodstream through an intravenous line, similar to a blood transfusion. These cells naturally find their way to the bone marrow, where they begin producing new blood and immune cells over the following weeks. The period immediately after transplant is extremely dangerous, as patients have virtually no immune system and are extraordinarily vulnerable to infections. They require intensive medical care, often in isolation units with special air filtration systems.^[9]

Successful stem cell transplantation has dramatically improved survival rates for familial haemophagocytic lymphohistiocytosis. Studies show that with current protocols combining effective chemoimmunotherapy to control disease before transplant and improved transplant techniques, a significant proportion of patients can achieve long-term survival and normal quality of life. However, the transplant itself carries substantial risks, including infection, graft-versus-host disease where donor immune cells attack the patient’s tissues, organ damage from conditioning chemotherapy, and transplant failure.^[1]

Emerging Targeted Therapies in Clinical Trials

Recognizing the limitations and toxicities of standard treatment, researchers have been actively investigating new drugs that target specific components of the immune dysfunction in familial haemophagocytic lymphohistiocytosis. These targeted therapies aim to control the disease more precisely with fewer side effects than traditional chemotherapy, potentially improving outcomes for patients who respond poorly to conventional treatment or cannot tolerate its toxicity.^[7]

The most significant breakthrough in targeted therapy is emapalumab, a monoclonal antibody that neutralizes interferon-gamma, one of the key cytokines driving inflammation in familial haemophagocytic lymphohistiocytosis. Interferon-gamma is massively overproduced in this condition and plays a central role in activating macrophages and perpetuating the inflammatory cascade. Emapalumab binds to interferon-gamma molecules in the bloodstream, preventing them from activating their receptors on cells. This represents the first and only targeted therapy specifically approved for primary hemophagocytic lymphohistiocytosis after completion of Phase III clinical trials demonstrating its effectiveness in controlling disease activity.^[7]

Emapalumab is given as an intravenous infusion, typically starting at a dose that is then adjusted based on the patient’s response and interferon-gamma levels. Clinical trial results showed that many patients who were not responding adequately to conventional therapy experienced significant improvement when emapalumab was added to their treatment regimen. The drug proved particularly valuable as a bridge to stem cell transplantation for patients with severe, refractory disease. Side effects observed in trials included increased susceptibility to infections, as would be expected from blocking an important immune signaling molecule.^[7]

Beyond emapalumab, numerous other targeted agents are being explored in earlier-phase clinical trials. Researchers are investigating drugs that block other inflammatory cytokines involved in hemophagocytic lymphohistiocytosis, including interleukin-1 and interleukin-6. Medications like anakinra and tocilizumab, which target these pathways and are already used for other inflammatory conditions, are being tested in Phase II studies to determine if they can help control the cytokine storm in familial haemophagocytic lymphohistiocytosis.^[7]

Another innovative approach being studied involves drugs that directly modulate the function of natural killer cells and cytotoxic T cells, the immune cells that are defective in familial haemophagocytic lymphohistiocytosis. These therapies aim to either restore some function to the impaired cells or prevent them from causing damage while they are malfunctioning. Phase I trials of such agents are evaluating safety profiles and identifying appropriate doses for these novel mechanisms of action.^[7]

Several clinical trials are investigating the role of ruxolitinib, a drug that inhibits enzymes called Janus kinases (JAK). These enzymes are crucial for transmitting signals from multiple cytokine receptors, including those for interferons and interleukins. By blocking JAK enzymes, ruxolitinib can reduce the cellular response to multiple inflammatory signals simultaneously. Early Phase II results suggest that JAK inhibitors may help control inflammation in some patients with hemophagocytic lymphohistiocytosis, though more research is needed to define their role in treatment protocols.^[7]

Gene therapy represents an exciting frontier in research for familial haemophagocytic lymphohistiocytosis. Since the condition is caused by specific genetic mutations that prevent immune cells from functioning properly, the theoretical possibility exists to correct these defects by introducing functional copies of the affected genes into the patient’s own stem cells. Researchers are working on developing safe and effective gene therapy approaches, though these remain in early experimental stages and have not yet progressed to large-scale human trials for this particular condition.^[7]

Multi-targeted combination therapy is emerging as an important concept in treating hemophagocytic lymphohistiocytosis. Rather than relying on a single drug to address the complex immune dysfunction, researchers are exploring combinations of agents that block different components of the inflammatory cascade simultaneously. For example, trials are examining whether combining interferon-gamma blockade with interleukin-1 or interleukin-6 inhibition provides better disease control than either approach alone. These studies are helping to map out which cytokine pathways are most critical to target for optimal outcomes.^[7]

Most Common Treatment Methods

• Chemoimmunotherapy Protocols
  • HLH-94 and HLH-2004 treatment protocols using etoposide as the primary chemotherapy agent
  • High-dose corticosteroids, typically dexamethasone, to suppress inflammation and cytokine production
  • Cyclosporine to block T cell activation and proliferation
  • Intrathecal chemotherapy for patients with neurological involvement
• Allogeneic Hematopoietic Stem Cell Transplantation
  • Matched sibling donor transplant as the preferred option
  • Unrelated donor or partially matched family member transplant when sibling donors are unavailable
  • Umbilical cord blood transplantation as an alternative stem cell source
  • Conditioning regimens to prepare patients for transplant
• Targeted Immunotherapy
  • Emapalumab, a monoclonal antibody that neutralizes interferon-gamma
  • Cytokine blockers targeting interleukin-1 and interleukin-6 in clinical trials
  • JAK inhibitors like ruxolitinib being studied for cytokine storm control
• Supportive Care Measures
  • Blood product transfusions including red blood cells and platelets
  • Prophylactic antimicrobial medications to prevent infections
  • Intensive monitoring of blood counts, organ function, and inflammation markers